Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 2577

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 2577
---
 and two significant
customers at 79% and 13%, respectively) and 93% of total net product revenues (consisting of two significant customers at 72% and 21%,
respectively).

Currently, the Company has exclusive relationships with distributors
in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets.

Since the Company first started working on tafenoquine
all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it
would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient
(“API”).

Segment Information

Since its inception, the Company operates and
manages its business as a single identifiable segment, focused on the development and marketing of new medicines for the treatment and
prevention of infectious diseases. The determination of a single business segment is consistent with the consolidated financial information
regularly provided to the Company’s chief operating decision maker (“CODM”). 

The Company’s CODM is its Chief Executive
Officer, who reviews and evaluates consolidated net income or loss for purposes of evaluating performance, making operating decisions,
allocating resources, and planning and forecasting for future periods. The significant components of consolidated net income or loss
regularly provided to the CODM include net product revenues and the significant expense categories presented in the accompanying Consolidated
Statements of Operations and Comprehensive Loss (cost of revenues, research and development, and general and administrative expenses).
These are presented at the consolidated level and used by the CODM to monitor budgeted versus actual results to make key operating decisions.
The information and operating expense categories presented in the accompanying Consolidated Statements of Operations and Comprehensive
Loss are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.

The measure of segment assets that is regularly
reported to the CODM includes cash and cash equivalents and short-term investments, each as reported on the Consolidated Balance Sheets.
Total consolidated cash and cash equivalents and short-term investments were $3,387,825 and $2,142,485 as of December 31, 2024 and December
31, 2023, respectively.

F-14

Revenue Recognition

The Company recognizes revenue in accordance
with FASB ASC Topic No. 606, Revenue from Contracts with Customers (“ASC 606”). Revenues are recognized when control
is transferred to customers in amounts that reflect the consideration the Company expects to be